Targeted therapy for acute myeloid leukemia with FLT3-ITD mutation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a targeted therapy that specifically attacks leukemia cells with the FLT3-ITD gene change. If you have this mutation, the goal is to see if adding this drug to standard chemotherapy improves your chances of going into remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with acute myeloid leukemia (AML) and have the FLT3-ITD gene change.
- You need to be between 18 and 75 years old and generally well enough to receive standard chemotherapy.
- Your white blood cell count must be below a certain level (procedures to lower it are allowed).
- Your liver and kidney function must be within acceptable limits.
- You cannot have been treated for AML before, except for emergency measures to control very high white blood cell counts.
- You cannot have taken FLT3 inhibitor drugs in the past, and you must not have other serious medical conditions like severe heart or lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a targeted drug called gilteritinib to a standard two-drug combination (venetoclax and azacitidine) for people with a specific genetic change (FLT3 mutation) in their acute myeloid leukemia (AML). The goal is to see if the three drugs together work better than the two alone, for patients who cannot tolerate strong chemotherapy.
This trial compares a new combination treatment to standard chemotherapy plus a targeted drug (called an FLT3 inhibitor) in people with AML that has a FLT3 mutation. The goal is to see if the new approach works better and helps improve outcomes.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a three-drug combination for people with acute myeloid leukemia (AML) that did not respond to or came back after previous treatment with azacitidine and venetoclax. The goal is to see if adding gilteritinib can help control the leukemia.
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
Hear when a new AML (Acute Myeloid Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.